Psilocybin benefits: what clinical research has and has not shown

“Psilocybin benefits” and “magic mushrooms benefits” are common searches, and the honest answer is narrower than most search results suggest. Researchers have tested psilocybin, the main psychoactive compound in magic mushrooms, in a range of conditions. In some trials, participants who received it did better on the main measure than a comparison group. In others they did not. Almost every study was small, short or hard to blind.

This page is a map. It summarises, condition by condition, what our detailed articles found in the published research, and links to each one so you can read the design, numbers and limits in full. Where we add something new, such as smoking or anorexia studies, we say so and label it. For background on the compound itself, start with what psilocybin is and what magic mushrooms are.

Browse all studies: our psilocybin studies library lists the major published psilocybin studies, each with a plain-English summary of what it found.

What does “benefit” mean in psilocybin research?

In a clinical trial, a benefit is a measured difference on a pre-chosen outcome, such as a depression rating score or the share of heavy drinking days, between people given psilocybin and people given something else. It is an average across a group, under specific conditions, over a specific period. It is not a promise about any individual.

Those conditions matter. In the trials summarised here, participants were screened and some groups were excluded, for example people with a history of psychosis or high suicide risk. Sessions were supervised, and psilocybin was paired with preparation and psychological support. Findings from those settings do not transfer to use outside them, and none of these studies tested self-treatment.

Comparison groups vary too, and that shapes how big a result looks. A waiting list, a daily antidepressant, a very low dose and an inactive-looking pill have all been used. Because psilocybin’s effects are strong and noticeable, many participants can tell what they received. A 2021 review argued that effect sizes in psychedelic trials are therefore likely overestimated (Muthukumaraswamy et al., 2021).

Psilocybin and mental health: what has research found, condition by condition?

The table below compresses our detailed articles into one view. Each row names the strongest kind of study we found for that condition, not the most positive one. Our evidence labels mean: established, shown in peer-reviewed studies and not seriously disputed; limited, several controlled trials but mixed or modest results with real design problems; preliminary, early, small, uncontrolled or indirect; unresolved, the data point different ways.

Read the table as a list of open questions, not a menu of uses. Even the strongest row, depression, rests on trials that disagree with one another, and no row describes a condition where psilocybin is an approved treatment in Canada.

Can magic mushrooms help with depression? What the trials found

The trials studied psilocybin given in supervised clinical sessions, which is not the same as using mushrooms on your own, and the results are mixed. In a 2021 waiting-list trial of 27 adults, clinician-rated scores four weeks after treatment averaged 8.5 in the immediate group and 23.5 in controls, but a waiting list is not a placebo (Davis et al., 2021). In a 59-person trial against the antidepressant escitalopram, the primary outcome was -8.0 with psilocybin and -6.0 with escitalopram, not a significant difference (Carhart-Harris et al., 2021).

Larger trials followed. In a 233-person trial of a proprietary formulation in treatment-resistant depression, the higher dose beat a very low control dose by 6.6 points at week 3, though sustained response at 12 weeks did not clearly support the result, and adverse events occurred in 77% (Goodwin et al., 2022). In a 104-person trial, scores at day 43 were 12.3 points lower with psilocybin than with niacin, and the authors say functional unblinding was likely (Raison et al., 2023).

The most recent trial we found is EPISODE, a German phase 2b trial with an active placebo. Response at week 6 was 17.0%, 12.5% and 10.6% across the arms compared, the first planned comparison was not significant, and 86% of participants correctly identified the higher dose. Its authors call it an inconclusive trial (Mertens et al., 2026). A 2025 meta-analysis found that control groups in psilocybin trials improved less than control groups in antidepressant trials, which its authors say might mean psilocybin’s efficacy is overestimated by comparison (Hieronymus et al., 2025).

Evidence: limited. There are more controlled trials here than for any other condition, but they disagree, and blinding is a real problem. Full details are in our article on psilocybin depression trials. People taking antidepressants face separate questions, covered in magic mushrooms and antidepressants.

What about alcohol and smoking?

Alcohol use disorder

In a 2022 double-blind trial of 95 people, the share of heavy drinking days over 32 weeks was 9.7% with psilocybin and 23.6% with an active placebo, but about 94% of participants guessed their group correctly (Bogenschutz et al., 2022). A 2025 Swiss trial of 37 people found no significant difference in abstinence or alcohol use at 4 weeks or 6 months (Rieser et al., 2025). A 30-person French pilot reported more abstinence at 12 weeks with psilocybin than with a very low-dose control, but blinding was imperfect and the relapse difference was not significant (Luquiens et al., 2025).

Evidence: unresolved. Our article on psilocybin and alcohol use disorder sets out every study, including trials registered at Canadian sites.

Tobacco smoking (preliminary)

This is not covered in our other articles, so we read the studies for this page. In a 2014 open-label pilot at Johns Hopkins, 15 psychiatrically healthy smokers received psilocybin within a structured smoking-cessation programme. At 6 months, 12 of 15 (80%) showed biochemically checked seven-day abstinence. The authors wrote that the open-label design does not allow definitive conclusions about efficacy (Johnson et al., 2014).

The same group published a pilot randomized trial in 2026. 82 psychiatrically healthy adult smokers received either one psilocybin session or 8 to 10 weeks of nicotine patch treatment, and both groups received 13 weeks of cognitive behavioural therapy. At 6 months, 40.5% of the psilocybin group and 10.0% of the patch group had biochemically verified prolonged abstinence. No serious adverse events were attributed to either treatment (Johnson et al., 2026).

The limits are large. Participants and investigators knew who received what, there was no placebo, the data came from one centre, collected between 2015 and 2023, and only psychiatrically healthy smokers took part (Johnson et al., 2026). Evidence: preliminary. A blinded, multi-site trial would be needed to know whether the difference holds.

Cancer-related distress, PTSD and anorexia

Anxiety and depression in people with life-threatening cancer

A 12-person pilot in 2011 reported lower anxiety scores at 1 and 3 months after psilocybin (Grob et al., 2011). Two 2016 double-blind crossover trials then gave psilocybin with psychotherapy to adults with cancer. In the 29-person New York trial, anxiety and depression scores were lower with psilocybin than with niacin before the crossover (Ross et al., 2016). In the 51-person Baltimore trial, clinician-rated response at 6 months was 78% for depression and 83% for anxiety, but the crossover ended the double-blind comparison at 5 weeks (Griffiths et al., 2016).

A 2026 meta-analysis reported lower depression scores in randomized trials and mixed results on anxiety, and called its findings preliminary because of few studies, high heterogeneity, blinding and expectancy problems, and frequent combination with psychotherapy (Moshfeghinia et al., 2026). Evidence: preliminary. Read more in psilocybin and end-of-life distress.

Post-traumatic stress disorder

For psilocybin itself, we found two small open-label studies with results. One, sponsored by COMPASS Pathfinder, gave a single session to 22 adults and reported a score change of -29.9 at week 4, with 117 adverse events and none serious (McGowan et al., 2026). The other gave two sessions to 12 US veterans with severe, treatment-resistant PTSD and reported that 9 of 12 responded (Armstrong et al., 2026). Neither had a comparison group.

Evidence: preliminary. Our PTSD evidence article explains why MDMA results are often confused with psilocybin results, and lists registered trials, including some in Toronto and Calgary.

Anorexia nervosa (preliminary)

This is also new on this page. A phase 1 open-label study in Nature Medicine gave a single psilocybin session, with psychological support, to 10 adult women with anorexia nervosa or the condition in partial remission. Its main aim was safety, tolerability and feasibility. The authors reported no clinically significant changes in heart tracings, vital signs or suicidality; two participants had low blood sugar without symptoms that resolved within 24 hours; and all adverse events were mild and transient (Peck et al., 2023).

That is a feasibility result. With 10 people and no control group (Peck et al., 2023), it cannot show whether psilocybin changes the course of anorexia. Evidence: preliminary.

Microdosing, creativity and “rewiring” the brain

Many claimed magic mushrooms benefits come from microdosing, the repeated use of very small amounts. In a self-blinding study, 191 participants completed the protocol; everyone improved over 4 weeks, but the placebo group improved just as much (Szigeti et al., 2021). A 34-person double-blind study of psilocybin mushrooms found no evidence for enhanced well-being, creativity or cognition, and concluded that expectation underlies at least some of the anecdotal benefits (Cavanna et al., 2022). A 2026 systematic review rated the certainty of microdosing evidence as low (Page et al., 2026). Evidence: preliminary. See what controlled microdosing trials show.

For creativity, the best-controlled study gave psilocybin or placebo to 60 adults. People felt more insightful during the experience but did worse on structured creativity tasks, and one measure of novel ideas was higher a week later (Mason et al., 2021). Evidence: preliminary. Details are in psilocybin, creativity and openness.

“Rewiring” is a popular word, not a finding. In mice, one dose raised the density and size of dendritic spines by about 10% within 24 hours (Shao et al., 2021). A 2026 study of fifteen healthy volunteers found no statistically significant overall increase in a marker of synapse density a week after a dose (Johansen et al., 2026). Evidence: established for changes while psilocybin is active; preliminary for lasting change. See does psilocybin rewire the brain?.

What is psilocybin used for in Canada today?

Outside research and a few tightly controlled access routes, it is not used as a medicine. As of 24 October 2026, Health Canada’s page (last modified 20 October 2026) states that production, sale and possession of magic mushrooms are illegal in Canada, and that there are no approved therapeutic products containing psilocybin in Canada or elsewhere (Health Canada). Approval positions can change, so check that page for the current position.

Our guide to psilocybin-assisted therapy in Canada describes three lawful routes, all led by a regulated practitioner or researcher: clinical trials, the Special Access Program and individual section 56(1) exemptions (Health Canada). None of these is a way for a person to obtain psilocybin on their own, and this article does not advise on any of them.

The product closest to approval elsewhere is COMP360, a psilocybin formulation studied in treatment-resistant depression. Its sponsor reported that two phase 3 trials met their primary endpoints, with differences of 3.6 and 3.8 points on a depression rating scale (Form 10-Q). Those are company reports, and as of 4 October 2026 we had found no FDA approval and no peer-reviewed phase 3 publication. A U.S. decision would not automatically change anything in Canada. See COMP360 and the FDA: what it means for Canada.

What side effects and risks did studies report?

Adverse events were common in the trials, even with screening and supervision. In the 233-person depression trial, 77% of participants reported adverse events, including headache, nausea and dizziness, and suicidal ideation, suicidal behaviour or self-injury occurred in all dose groups (Goodwin et al., 2022). In the 104-person trial, 88% of the psilocybin group and 61% of the niacin group reported at least one adverse event (Raison et al., 2023). EPISODE reported higher suicidal ideation on dosing days after the higher dose and one case of hallucinogen persisting perception disorder, a lasting disturbance in perception (Mertens et al., 2026).

Side effects may also be under-described. A 2025 systematic review of 24 psilocybin-assisted therapy trials rated the quality of side-effect reporting high in only 6 and low or very low in 14. All 9 randomized trials it assessed had a high risk of bias for side-effect outcomes. The authors say reporting is improving but inconsistent, and that current uncertainty about side effects should be part of any discussion with patients (Marinis et al., 2025).

Outside a trial there is no screening, no support and no certainty about what a mushroom contains. For everyday risk information, read are magic mushrooms safe?, can magic mushrooms cause psychosis? and our explainer on HPPD.

Why are the results still described as early and mixed?

• Blinding is hard. Most participants in several trials guessed whether they had received psilocybin, so expectancy may inflate results.
• Therapy is part of the package. Psilocybin was given with preparation and psychological support, so studies cannot fully separate the drug from the care around it.
• Samples are small and narrow. Many trials had a few dozen people, and several were predominantly White and, where stated, higher-income.
• Follow-up is short. Controlled comparisons usually lasted weeks to a few months; longer follow-ups we found had no comparison group.
• Many groups were excluded. People with psychosis, mania, high suicide risk or other conditions were often left out, so the studies say little about them.
• Newer, larger trials disagree with older, smaller ones. The earliest depression trial reported the largest effects; the most recent missed its primary endpoint.

What is still unknown?

• How much of any measured improvement comes from psilocybin itself, and how much from expectancy, unblinding and therapy.
• Whether results hold in larger, more diverse groups and in people the trials excluded.
• How long any effect lasts when a controlled comparison is kept.
• How psilocybin compares with established treatments. Among the trials summarised here, only those in depression and smoking compared psilocybin with an established treatment, and neither settles the question.
• The full safety picture, given inconsistent side-effect reporting.
• Whether the smoking and anorexia signals survive blinded, controlled trials.

Put simply, psilocybin is a subject of serious research, not an established treatment. The benefits reported so far are trial outcomes under clinical conditions, and the people who ran those trials are the first to say more and larger studies are needed. If you are struggling, a health professional is the right starting point.

Shroomverse sells mushroom products. This article is general information about clinical research. It is not medical, legal or purchasing advice, and it does not recommend any product.